Acrivon Therapeutics, Inc.
ACRV
$2.57
$0.041.58%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 13.20% | -6.74% | 13.80% | -1.74% | -19.38% |
| Total Depreciation and Amortization | 4.18% | 7.72% | 2.64% | 20.72% | 10.09% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.17% | 8.97% | 20.50% | 12.95% | 0.26% |
| Change in Net Operating Assets | 2,719.23% | 101.35% | -281.80% | -2.26% | 9.79% |
| Cash from Operations | 26.05% | 14.97% | -12.53% | -0.21% | -24.60% |
| Capital Expenditure | -82.35% | -750.00% | 92.99% | 16.38% | -621.90% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -65.85% | 3.49% | 26.46% | -10.36% | 119.34% |
| Cash from Investing | -69.61% | 1.23% | 33.32% | -9.99% | 118.19% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -- | -- | -100.00% |
| Repurchase of Common Stock | -20.62% | 71.80% | 46.83% | 45.95% | -134.71% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 100.00% | -100.57% |
| Cash from Financing | -20.62% | 71.72% | 46.99% | 56.98% | -101.22% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -336.48% | 513.25% | 81.53% | -27.66% | -113.16% |